NCT05987826View on ClinicalTrials.gov

Study of Furmonertinib as Neoadjuvant Therapy for Resectable Stage Ⅱ-ⅢB EGFR Sensitive Mutant NSCLC

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

August 31, 2023

Primary Completion Date

August 31, 2024

Study Completion Date

December 31, 2025

Conditions
Non-Small Cell Lung Cancer
Interventions
DRUG

Furmonertinib

Furmonertinib 80mg QD oral 8 weeks.

All Listed Sponsors
collaborator

Xuhui Central Hospital, Shanghai

OTHER

collaborator

Shanghai Minhang Central Hospital

OTHER

collaborator

Shanghai Zhongshan Hospital Qingpu Branch

UNKNOWN

collaborator

Ningbo No. 1 Hospital

OTHER

lead

Shanghai Zhongshan Hospital

OTHER

NCT05987826 - Study of Furmonertinib as Neoadjuvant Therapy for Resectable Stage Ⅱ-ⅢB EGFR Sensitive Mutant NSCLC | Biotech Hunter | Biotech Hunter